Evidence map›Paper›PMID 39284275›Full record

ArticleClinics (Sao Paulo, Brazil)2024

Resistance and virulence genes characteristic of a South Asia Clade (I) Candida auris strain isolated from blood in Beijing.

Jing-Xian Yang, Guan-Nan Ma, Ya-Tong Li, Yu-Peng Shi, Guo-Wei Liang

Abstract read
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jing-Xian YangDepartment of Clinical Laboratory, Aerospace Center Hospital, Beijing, 100049 China.
Guan-Nan MaZhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Hangzhou, 310000 China.
Ya-Tong LiZhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Hangzhou, 310000 China.
Yu-Peng ShiZhejiang Key Laboratory of Digital Technology in Medical Diagnostics, Hangzhou, 310000 China.
Guo-Wei LiangDepartment of Clinical Laboratory, Aerospace Center Hospital, Beijing, 100049 China. Electronic address: LGW721@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCandida auris is a globally disseminated invasive ascomycetous yeast, that imposes a substantial burden on healthcare systems. It has been documented to have spread to over 40 countries across six continents, necessitating in-depth comprehension through advanced techniques like Whole-Genome Sequencing.

methodThis study entailed the isolation and Whole-Genome Sequencing of a fluconazole-resistant C. auris strain (CA01) obtained from a patient's blood in Beijing. Genome analysis was conducted to classify the strain, and molecular docking was performed to understand the impact of mutations on drug resistance.

resultsGenome analysis revealed that CA01 belongs to the South Asia Clade (I) and shares the closest genetic relationship with previously reported strains BJCA001 and BJCA002. Notably, unlike BJCA001, CA01 exhibits significant resistance to fluconazole primarily due to the A395T mutation in the ERG11 gene. Molecular docking studies demonstrated that this mutation leads to geometric changes in the active site where fluconazole binds, resulting in decreased binding affinity. Additionally, the present findings have identified several core virulence genes in C. auris, such as RBF1. DISCUSSION: The findings from this study expand the understanding of the genetic diversity and adaptive mechanisms of C. auris within the South Asia Clade (I). The observed fluconazole resistance driven by the ERG11 mutation A395T highlights the need for heightened awareness and adaptation in clinical treatment strategies in China. This study provides critical insights into drug resistance and virulence profiles at a genetic level, which could guide future therapeutic and management strategies for C. auris infections.

Indexed as

Antifungal AgentsCandida aurisDrug Resistance, FungalFluconazoleAsia, SouthernBeijingCandidiasisHumansMicrobial Sensitivity TestsMolecular Docking SimulationMutationVirulenceWhole Genome SequencingAntifungal AgentsFluconazoleCandida aurisFluconazole resistanceGenomicMolecular dockingVirulence

Identifiers

PMID39284275
PMCPMC11419799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.